Which statement best reflects the relationship between lipid-based and conventional amphotericin B formulations?

• A. They are interchangeable
• B. They have identical dosing
• C. They are not interchangeable and require different dosing
• D. They are never used in neonates

Answer: (A)

The main idea is that different formulations of amphotericin B behave differently in the body. Lipid-based formulations, such as liposomal amphotericin B and amphotericin B lipid complex, have altered pharmacokinetics and tissue distribution and typically cause less nephrotoxicity than the conventional amphotericin B deoxycholate. Because of these differences, you cannot substitute one mg/kg dose for another across formulations without adjusting and monitoring; the dosing regimens are not interchangeable. In neonates, this means distinct dosing strategies: conventional amphotericin B is given at a lower mg/kg/day, while lipid formulations require higher mg/kg/day to achieve similar antifungal exposure, all while balancing toxicity risk. In short, formulation choice dictates dosing and safety, so they are not interchangeable.